BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 31727944)

  • 1. The DOT1L inhibitor Pinometostat decreases the host-response against infections: Considerations about its use in human therapy.
    Marcos-Villar L; Nieto A
    Sci Rep; 2019 Nov; 9(1):16862. PubMed ID: 31727944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring drug delivery for the DOT1L inhibitor pinometostat (EPZ-5676): Subcutaneous administration as an alternative to continuous IV infusion, in the pursuit of an epigenetic target.
    Waters NJ; Daigle SR; Rehlaender BN; Basavapathruni A; Campbell CT; Jensen TB; Truitt BF; Olhava EJ; Pollock RM; Stickland KA; Dovletoglou A
    J Control Release; 2015 Dec; 220(Pt B):758-65. PubMed ID: 26385168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Stein EM; Garcia-Manero G; Rizzieri DA; Tibes R; Berdeja JG; Savona MR; Jongen-Lavrenic M; Altman JK; Thomson B; Blakemore SJ; Daigle SR; Waters NJ; Suttle AB; Clawson A; Pollock R; Krivtsov A; Armstrong SA; DiMartino J; Hedrick E; Löwenberg B; Tallman MS
    Blood; 2018 Jun; 131(24):2661-2669. PubMed ID: 29724899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Pinometostat (EPZ-5676) Treatment-Emergent Resistance in
    Campbell CT; Haladyna JN; Drubin DA; Thomson TM; Maria MJ; Yamauchi T; Waters NJ; Olhava EJ; Pollock RM; Smith JJ; Copeland RA; Blakemore SJ; Bernt KM; Daigle SR
    Mol Cancer Ther; 2017 Aug; 16(8):1669-1679. PubMed ID: 28428443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.
    Waters NJ
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):891-901. PubMed ID: 28229434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon- Stimulation Elicited by the Influenza Virus Is Regulated by the Histone Methylase Dot1L through the RIG-I-TRIM25 Signaling Axis.
    Marcos-Villar L; Nistal-Villan E; Zamarreño N; Garaigorta U; Gastaminza P; Nieto A
    Cells; 2020 Mar; 9(3):. PubMed ID: 32188146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
    Sarno F; Nebbioso A; Altucci L
    Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibitor of AF9/ENL-DOT1L/AF4/AFF4 interactions suppresses malignant gene expression and tumor growth.
    Wu F; Nie S; Yao Y; Huo T; Li X; Wu X; Zhao J; Lin YL; Zhang Y; Mo Q; Song Y
    Theranostics; 2021; 11(17):8172-8184. PubMed ID: 34373735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of
    Lonetti A; Indio V; Laginestra MA; Tarantino G; Chiarini F; Astolfi A; Bertuccio SN; Martelli AM; Locatelli F; Pession A; Masetti R
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.
    Dafflon C; Craig VJ; Méreau H; Gräsel J; Schacher Engstler B; Hoffman G; Nigsch F; Gaulis S; Barys L; Ito M; Aguadé-Gorgorió J; Bornhauser B; Bourquin JP; Proske A; Stork-Fux C; Murakami M; Sellers WR; Hofmann F; Schwaller J; Tiedt R
    Leukemia; 2017 Jun; 31(6):1269-1277. PubMed ID: 27840424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
    Lillico R; Lawrence CK; Lakowski TM
    J Proteome Res; 2018 Aug; 17(8):2657-2667. PubMed ID: 29972300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
    Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
    Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.
    Richter WF; Shah RN; Ruthenburg AJ
    Elife; 2021 Jul; 10():. PubMed ID: 34263728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
    Daigle SR; Olhava EJ; Therkelsen CA; Basavapathruni A; Jin L; Boriack-Sjodin PA; Allain CJ; Klaus CR; Raimondi A; Scott MP; Waters NJ; Chesworth R; Moyer MP; Copeland RA; Richon VM; Pollock RM
    Blood; 2013 Aug; 122(6):1017-25. PubMed ID: 23801631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
    Liu W; Deng L; Song Y; Redell M
    PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias.
    Yi Y; Ge S
    J Hematol Oncol; 2022 Mar; 15(1):35. PubMed ID: 35331314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MLL leukemia and future treatment strategies.
    Marschalek R
    Arch Pharm (Weinheim); 2015 Apr; 348(4):221-8. PubMed ID: 25740345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
    Klaus CR; Iwanowicz D; Johnston D; Campbell CA; Smith JJ; Moyer MP; Copeland RA; Olhava EJ; Scott MP; Pollock RM; Daigle SR; Raimondi A
    J Pharmacol Exp Ther; 2014 Sep; 350(3):646-56. PubMed ID: 24993360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNA hsa-miR-324-5p Suppresses H5N1 Virus Replication by Targeting the Viral PB1 and Host CUEDC2.
    Kumar A; Kumar A; Ingle H; Kumar S; Mishra R; Verma MK; Biswas D; Kumar NS; Mishra A; Raut AA; Takaoka A; Kumar H
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.